Potassium
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Potassium: From Electrolyte Replacement (Hypokalemia) to Hypertensive Disorder
One-Sentence Summary
Potassium is an essential electrolyte, conventionally used for potassium replacement/supplementation in hypokalemia and as part of routine electrolyte management. The TxGNN model predicts it may be effective for Hypertensive Disorder, with ~44 registered clinical trials (many of low direct relevance) and 21 publications currently reviewed for this direction, including several high-quality meta-analyses and a large NEJM RCT on potassium-enriched salt substitutes.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file in this Evidence Pack (no TFDA/US license records); potassium is generically used for hypokalemia correction / electrolyte replacement |
| Predicted New Indication | Hypertensive Disorder |
| TxGNN Prediction Score | 99.16% |
| Evidence Level | L2 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed formal mechanism-of-action (MOA) data for this candidate is currently unavailable in the Evidence Pack (DG002, High severity). Based on established physiology, however, potassium promotes natriuresis, suppresses renin-angiotensin-aldosterone system (RAAS) activity, and reduces vascular smooth muscle tone — this is the core mechanistic basis underlying the DASH diet and WHO dietary recommendations for blood pressure control.
Unlike a typical drug-repurposing candidate moving between two disease areas, potassium’s link to hypertension is an already well-established nutrient-disease relationship rather than a novel mechanistic hypothesis generated purely from knowledge-graph similarity. This is reflected in the evidence base: large-scale meta-analyses, systematic reviews, and a landmark cluster-randomized NEJM trial (potassium-enriched salt substitution) all support an inverse dose-response relationship between potassium intake and blood pressure.
The main caveat is that this evidence largely concerns dietary potassium intake or salt substitution, not a discrete pharmaceutical potassium product dosed for hypertension indication. Clinical translation into a formal antihypertensive indication would still require dose-ranging and safety validation, particularly given the narrow therapeutic window of potassium and hyperkalemia risk in renal impairment.
Clinical Trial Evidence
Note: Many KG-matched trials in the raw evidence set were graded “C” (low relevance/noise — e.g., unrelated interventions co-occurring with a “hypertension” label). The table below lists the trials with a direct, interpretable link to potassium and blood pressure/electrolyte physiology.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03809884 | Phase 3 | Completed | 7 | Adaptive trial comparing dietary counseling vs. additional potassium supplement to increase potassium intake in patients with high blood pressure |
| NCT02653560 | Phase 4 | Completed | 30 | Liquid potassium-magnesium citrate tested for blood pressure control, building on DASH diet rationale (K/Mg/alkali components) |
| NCT05145309 | Phase 2 | Not yet recruiting | 45 | Potassium-magnesium citrate for prevention/treatment of hypertension specifically in African American patients |
| NCT03569020 | N/A | Completed | 43 | DASH diet (high-potassium) effects on blood pressure/uric acid in adults with hyperuricemia and gout |
| NCT05155436 | Phase 4 | Completed | 1090 | Prevalence/incidence of dyskalemia (hypo/hyperkalemia) in hypertensive patients starting fixed-dose telmisartan/amlodipine — relevant to potassium monitoring during antihypertensive therapy |
| NCT01224314 | N/A | Completed | 24 | Direct hemodynamic study: rapid changes in dialysate potassium concentration produce measurable blood pressure effects (“rebound hypertension”) |
| NCT05222191 | Phase 2 | Unknown | 24 | Spironolactone (potassium-retaining) vs. chlorthalidone in CKD-associated hypertension; hyperkalemia risk directly relevant to potassium safety |
| NCT02452749 | N/A | Completed | 30 | Safety/tolerability of a cardiovascular dietary supplement (includes potassium) in adults with borderline/mild hypertension |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34459569 | 2021 | RCT (cluster) | New England Journal of Medicine | Large cluster-RCT: sodium-reduced, potassium-enriched salt substitute lowered cardiovascular events and death |
| 32500831 | 2020 | Meta-analysis of RCTs | Journal of the American Heart Association | Dose-response meta-analysis showing potassium supplementation lowers blood pressure across trials ≥4 weeks |
| 23558164 | 2013 | Systematic Review | BMJ | Increased potassium intake associated with reduced cardiovascular risk factors and stroke risk |
| 39472546 | 2025 | Review | Hypertension Research | Role of dietary potassium and salt substitution in prevention/management of hypertension |
| 37772757 | 2024 | Review | American Journal of Hypertension | State-of-the-art review on potassium’s role in blood pressure regulation |
| 10979053 | 2000 | Clinical Practice Guideline | Archives of Internal Medicine | National Council on Potassium in Clinical Practice guidelines for potassium replacement |
| 27455317 | 2016 | Review | Nutrients | Potassium bioavailability and its relationship to hypertension and glucose control |
| 29771736 | 2018 | Review | Current Opinion in Cardiology | Dietary approaches (including potassium intake) for hypertension prevention/management |
| 30190007 | 2018 | Review | Journal of the American College of Cardiology | Inadequate dietary potassium identified as a modifiable environmental risk factor for hypertension |
| 25016398 | 2014 | Review | Seminars in Nephrology | Interaction of sodium surfeit and potassium deficiency as the chief driver of primary hypertension risk |
US Market Information
This drug currently has no marketing authorizations on file in the Evidence Pack (market status: Not Marketed, 0 licenses). No dosage form or approved-indication data is available for review.
Safety Considerations
Please refer to the package insert for safety information. No key warnings, contraindications, or drug-drug interaction data are currently available in this Evidence Pack (flagged as Blocking data gap, DG001 — TFDA label/warnings not yet retrieved).
Given potassium’s known narrow therapeutic index, any forward evaluation should explicitly prioritize hyperkalemia risk assessment (especially in renal impairment, concurrent RAAS-inhibitor/potassium-sparing diuretic use) once label data is obtained.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The potassium–blood pressure relationship is supported by strong epidemiological and interventional evidence, including a landmark NEJM cluster-RCT and multiple meta-analyses/systematic reviews, giving this candidate an L2 evidence level. However, this reflects a nutrient-disease relationship rather than a validated pharmaceutical indication, and safety data for a formal potassium drug product in hypertension is still absent.
To proceed, the following is needed:
- TFDA/FDA label warnings and contraindications (DG001, Blocking — required before any S1 safety screening)
- Formal mechanism-of-action documentation from DrugBank (DG002)
- Clarification of target population and dosing (dietary supplementation vs. pharmaceutical-grade potassium product) given hyperkalemia risk, particularly in renal impairment
- A dedicated safety monitoring plan (serum potassium, renal function) before any clinical development step
Note: Ranks 2–5 (pulmonary hypertension variants, malignant renovascular/hypertensive renal disease) are assessed as L4–L5 with no supporting mechanistic or clinical evidence and are recommended for Hold — several carry an increased hyperkalemia risk signal that runs counter to the proposed intervention.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.